Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Big Splash Acquisitions Could Drive Investors Toward Biotech

This article was originally published in The Pink Sheet Daily

Executive Summary

Regulatory setbacks have spooked public market investors, but recent deals could spark return, according to BioInvestor Forum panelists.

You may also be interested in...

Genzyme Wins AnorMED As Millennium Backs Out Of Bidding War

Genzyme gains late-stage product candidate Mozobil for approximately $580 mil.

Lilly Acquires ICOS To Bring Full Value Of Cialis In House

$2.1 bil. deal will allow Lilly to benefit from efficiencies in development, marketing and sales of the erectile dysfunction product.

Gilead Buys Myogen To Strengthen Pulmonology Franchise

The $2.5 bil. deal will add a late-stage candidate, ambrisentan, for the treatment of pulmonary arterial hypertension to Gilead's pipeline.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts